Sugi Predict

Sugi Predict / Compounds / SCHEMBL422917

SCHEMBL422917

SCHEMBL422917

NCCOCCOCCOCCNC(=O)COCC(=O)O

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 8/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CA2 P00918 5/20 0.37
▸ NCF1 P14598 1/20 0.35
▸ CA12 O43570 4/20 0.35
▸ CA1 P00915 4/20 0.35
▸ CA4 P22748 4/20 0.35
▸ CA9 Q16790 4/20 0.35
▸ CA14 Q9ULX7 4/20 0.35
▸ POLB P06746 1/20 0.34
▸ TSHR P16473 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ ENO1 P06733 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1404493 1.00 GLP1R (0.38) GLP1RSMN1; SMN2MEN1KMT2ACA2
SCHEMBL16943973 1.00 GLP1R (0.38) GLP1RSMN1; SMN2MEN1KMT2ACA2
SCHEMBL964367 1.00 GLP1R (0.38) GLP1RSMN1; SMN2MEN1KMT2ACA2
SCHEMBL1257485 0.97 GLP1R (0.41) GLP1RSMN1; SMN2MEN1KMT2ACA2
SCHEMBL30466662 0.97 GLP1R (0.41) GLP1RSMN1; SMN2MEN1KMT2ACA2
SCHEMBL20017289 0.93 MEN1 (0.41) GLP1RSMN1; SMN2MEN1KMT2ACA2
SCHEMBL2743010 0.91 SMN1; SMN2 (0.43) GLP1RSMN1; SMN2MEN1KMT2ACA2
SCHEMBL14453741 0.90 TSHR (0.43) GLP1RSMN1; SMN2TSHRRECQL
SCHEMBL24040332 0.89 MEN1 (0.41) GLP1RSMN1; SMN2MEN1KMT2ACA2
SCHEMBL24518424 0.87 SMN1; SMN2 (0.36) GLP1RSMN1; SMN2MEN1KMT2ACA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8182790-B2 Contrast agents GE HEALTHCARE AS (NO) 2012-05-22 — — US claimed
EP-1814598-B1 CONTRAST AGENTS TO TARGET EXTRACELLULAR MATRIX GE HEALTHCARE AS (NO) 2011-01-12 — — EP claimed
EP-2243496-A2 Contrast agents to target extracellular matrix GE HEALTHCARE AS (NO) 2010-10-27 — — EP claimed
US-20090208412-A1 Contrast Agents GE HEALTHCARE AS (NO) 2009-08-20 — — US claimed
EP-1814598-A2 CONTRAST AGENTS TO TARGET EXTRACELLULAR MATRIX GE Healthcare AS (NO) 2007-08-08 — — EP claimed
WO-2006054904-A2 CONTRAST AGENTS TO TARGET EXTRACELLULAR MATRIX GE HEALTHCARE AS (NO) 2006-05-26 — — WO claimed
WO-2025233638-A1 RADIOPHARMACEUTICAL IMAGING METHOD OF ADENOMYOSIS SERAC HEALTHCARE LTD (GB) 2025-11-13 — — WO disclosed
US-20250186633-A1 METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS SERAC HEALTHCARE LTD (GB) 2025-06-12 — — US disclosed
EP-4486396-A1 METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS Serac Healthcare Ltd (GB) 2025-01-08 — — EP disclosed
CN-118785926-A Imaging integrin expression and intrauterine method for imaging a site of endometriosis 赛瑞科医疗有限公司 2024-10-15 — — CN disclosed
WO-2023166305-A1 METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS SERAC HEALTHCARE LTD (GB) 2023-09-07 — — WO disclosed
US-11723991-B2 Radiopharmaceutical compositions SERAC HEALTHCARE LIMITED (GB) 2023-08-15 — — US disclosed
EP-2648767-B1 RADIOTRACER COMPOSITIONS GE HEALTHCARE LTD (GB) 2023-03-15 — — EP disclosed
EP-1549317-A1 IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES GE Healthcare Limited (GB) 2005-07-06 — — EP disclosed
WO-2005049005-A1 INHIBITOR IMAGING AGENTS GE HEALTHCARE LIMITED (GB) 2005-06-02 — — WO disclosed
WO-2005044313-A2 CONJUGATES OF ANGIOTENSIN II AND AN IMAGING MOIETY AMERSHAM HEALTH AS (NO) 2005-05-19 — — WO disclosed
US-20050070466-A1 Diagnostic imaging agents; targeting vectors which bind to integrin receptors; bicyclic arginine-glycine-aspartic acid derivatives; stablility; reduced background interference GE HEALTHCARE LIMITED (GB) 2005-03-31 — — US disclosed
WO-2004032936-A1 IMPROVED IMAGING AGENTS COMPRISING BARBITURIC ACID DERIVATIVES AMERSHAM PLC (GB) 2004-04-22 — — WO disclosed
EP-1404371-A2 PEPTIDE-BASED COMPOUNDS FOR TARGETING INTERGIN RECEPTORS Amersham Health AS (NO) 2004-04-07 — — EP disclosed
WO-2003006491-A2 PEPTIDE-BASED COMPOUNDS FOR TARGETING INTERGIN RECEPTORS AMERSHAM HEALTH AS (NO) 2003-01-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208412-A1 Contrast Agents COL2A1, COL1A1, COL14A1 GLP1R 1809/4885SMN1; SMN2 1641/4885MEN1 443/4885
US-11723991-B2 Radiopharmaceutical compositions TYMP, KIT, CHEK1 GLP1R 1234/4885SMN1; SMN2 2377/4885MEN1 8/4885
US-20050070466-A1 Diagnostic imaging agents; targeting vectors which bind to integrin receptors; bicyclic arginine-glycine-aspartic acid derivatives; stablility; reduced background interference ITGAV, ITGA2B, ITGB3 GLP1R 832/4885SMN1; SMN2 2707/4885MEN1 1529/4885
US-20250186633-A1 METHODS FOR IMAGING INTEGRIN EXPRESSION AND FOR IMAGING SITES OF ENDOMETRIOSIS ITGB3, ITGB5, ITGAV GLP1R 546/4885SMN1; SMN2 4538/4885MEN1 1442/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.